Drug Profile
Research programme: cholesterol-lowering therapies - Medicure/Universities of Manitoba and Ottawa Heart Institute
Latest Information Update: 02 May 2007
Price :
$50
*
At a glance
- Originator University of Manitoba; University of Ottawa Heart Institute
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 31 Jan 2005 Preclinical trials in Hypercholesterolaemia in Canada (unspecified route)